AVTR
Avantor, Inc.
AVTR has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AVTR overall, supported by stronger fundamentals.
AVTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
AVTR's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVTR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $15.62 | — |
| Cheap | 21x | $10.56 | -32% |
| Current | 31x | $15.62 | — |
| Fair | 41x | $20.70 | +33% |
| Expensive | 96x | $47.90 | +207% |
Historical ranges are pointers, not guarantees.
AVTR's PE is in its fair range at 31x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AVTR in the historical PE scenario, which offers more potential upside but is not a forecast.
AVTR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for AVTR, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AVTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | +75% |
| Q3 2026 | $0.50 | +$0.63 |
| Q2 2026 | -$0.84 | -185% |
| Q1 2026 | -$0.81 | -178% |
| Q4 2025 | -$0.78 | -175% |
| Q3 2025 | -$0.13 | -129% |
| Q2 2025 | $0.99 | +87% |
| Q1 2025 | $1.04 | +174% |
| Q4 2024 | $1.04 | +121% |
AVTR has returned to profit: it earned $0.50 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AVTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +4.6% |
| Q2 2026 | $1.7B | +0.5% |
| Q1 2026 | $1.6B | 0% |
| Q4 2025 | $1.7B | -1.4% |
| Q3 2025 | $1.6B | -5.3% |
| Q2 2025 | $1.7B | -1.1% |
| Q1 2025 | $1.6B | -5.9% |
| Q4 2024 | $1.7B | -2.1% |
AVTR's revenue has held roughly level: $1.7B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +48 points |
| Q2 2026 | 7.2% | -0.5 points |
| Q1 2026 | 6.3% | -3 points |
| Q4 2025 | 7.6% | -30 points |
| Q3 2025 | -40% | -47 points |
| Q2 2025 | 7.7% | -2.7 points |
| Q1 2025 | 9.3% | +0.6 points |
| Q4 2024 | 38% | +27 points |
AVTR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AVTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AVTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $156.2M | -9% |
| Q2 2026 | $140.6M | +13% |
| Q1 2026 | $25.2M | -69% |
| Q4 2025 | $117.2M | -20% |
| Q3 2025 | $171.7M | -16% |
| Q2 2025 | $124.8M | -47% |
| Q1 2025 | $81.3M | -24% |
| Q4 2024 | $145.8M | -27% |
AVTR's free cash flow has been positive every quarter for seven years: $439M over the past year, down 16% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AVTR on cash flow, with more consistent year-over-year improvement.
AVTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +3.7M shares |
| 1 year | -0.1% | -800K shares |
| 3 years | +0.4% | +2.4M shares |
| 5 years | +14% | +82.8M shares |
| Available history | +17% | +99.6M shares |
AVTR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AVTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q2 2026 | 28.9x | High |
| Q1 2026 | 29.1x | High |
| Q4 2025 | 21.8x | High |
| Q3 2025 | 5.4x | High |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.6x | Moderate |
AVTR's net debt is about 3.5 years of its operating earnings (EBITDA), down from 5.4 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AVTR on leverage, with a lower net debt burden relative to earnings.
AVTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.2 | Neutral |
| Stochastic | 62.4 | Neutral |
AVTR's weekly RSI is 64 (neutral) and its Stochastic is 62 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AVTR PE vs Healthcare Sector
| Metric | AVTR | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 21% above |
| PE % | 33 | 29 | 4 pts above |
AVTR is trading at 31x earnings, a 21% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AVTR on valuation relative to its sector.
AVTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.9 | 1.7% below |
| 20 week MA | $14.3 | 9.3% above |
| 50 week MA | $11.4 | 37% above |
| 100 week MA | $13.2 | 18% above |
| 200 week MA | $17.8 | 12% below |
AVTR's trend is mixed: it's above three of its five weekly moving averages, and 12% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AVTR on trend strength, trading above more of its moving averages.
AVTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $27.1 | +49% |
| 2021 | $27.1 | $41.3 | +52% |
| 2022 | $41.3 | $20.5 | -50% |
| 2023 | $20.5 | $22.8 | +11% |
| 2024 | $22.8 | $21.4 | -6.2% |
| 2025 | $21.4 | $11.4 | -47% |
| 2026 YTD | $11.4 | $15.6 | +37% |
AVTR is up 37% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AVTR on returns for 2026, with the stronger performance.